Information Provided By: 
Fly News Breaks for November 6, 2015
MDVN
Nov 6, 2015 | 07:15 EDT
Jefferies analyst Biren Amin points out Medivation reported that Xtandi sales grew 5% quarter-over-quarter driven by 6%-7% prescription growth and offset by inventory. Moderating Xtandi growth is in-line with his expectations. He lowered his price target for shares to $49 from $50 and keeps a Hold rating on the name.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
